electroCore, Inc. ECOR
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-06-22 |
| Shares Out. | 9,020,000 |
| Website | electrocore.com/ ↗ |
| Phone | 18009279800 |
| Employees | 83 |
| Revenue | $9.6M |
| Gross Profit | $8.4M |
| Net Income | -$5.3M |
| Free Cash Flow | -$6.9M |
| Total Assets | $15.5M |
| Total Liabilities | $21.2M |
| Equity | -$5.7M |
About electroCore, Inc.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.
electroCore, Inc. is a publicly traded company under the ticker symbol ECOR on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-07-01)